

3<sup>rd</sup> January, 2022

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051

**Scrip Code: BSE - 524500****Scrip Code: NSE - KILITCH**

**Sub: Disclosure Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Dear Sir,

In continuation of disclosure dated 31<sup>st</sup> December, 2022 submitted pursuant to provisions of regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details of the Kilitch Estro Biotech equity, foreign subsidiary of the company shares of which are being acquired are mentioned herein below;

Particulars	Details	
Name of the target entity	Kilitch Estro Biotech PLC	
Turnover (Rs.)	<b>31<sup>st</sup> March, 2022</b>	<b>21<sup>st</sup> March, 2021</b>
	9,44,85,529	54,25,327.86
Whether related party transaction	Yes	
Whether Promoter / Promoter Group/ Group Companies have any interest?	Mr. Mukund Mehta, Promoter and Mr. Bhavin Mehta, Promoter Group of the Company are directors of Kilitch Estro Biotech PLC	
Whether the transaction is on arm's length basis ?	Yes	
Industry to which the entity being acquired belongs	Pharmaceutical	
Object and effects of acquisition	To enhance investment of Kilitch Drugs (India) limited for long term return of investment	
Governmental or Regulatory approvals required for the acquisition	No prior approval is required.	
Indicative time period for completion of the acquisition	3- 6 months.	
Nature of Consideration	Cash Consideration	
Cost of Acquisition	Rs. 2,22,09,160	
Number of Shares acquired	14,436 shares	
Brief Background of the Company	Kilitch Estro Biotech PLC is engaged in manufacturing of Pharmaceutical Products	

MUKUND  
PRATAPRAI MEHTA

Digitally signed by MUKUND PRATAPRAI MEHTA  
DN: cn=MUKUND PRATAPRAI MEHTA, o=KILITCH DRUGS (INDIA) LTD., ou=KILITCH DRUGS (INDIA) LTD., email=MUKUND.PRATAPRAI@KILITCHDRUGS.COM, c=IN



WHO CERTIFIED



	incorporated in September, 2015 in Ethiopia, commenced its production in January, 2022
Pre and Post percentage of holding	67%. There is no change in percentage of holding of the Company because shares in same proportion is to be issued to other existing shareholders of Kilitch Estro Biotech PLC as well.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**MUKUND PRATAPRAI MEHTA**

Digitally signed by MUKUND PRATAPRAI MEHTA  
DN: cn=PERSONAL,  
pseudoym=de36996434193d53a7094312d9a7  
895b18e67a9e2503279166a31143c2144ac,  
serialCode=402037, cn=MUKUND PRATAPRAI MEHTA,  
serialNumber=424b6afed003b1ff1d748907a2c2  
a1855855109c7a4314c14803a6e1f9c2491,  
cn=MUKUND PRATAPRAI MEHTA  
Date: 2023.01.03 16:51:11 +05'30'

**Mukund Mehta**  
**Managing Director**

